-
5 days ago | 
cancernetwork.com | Tim Cortese
Retreatment with [177Lu]Lu-PSMA-617 (Pluvicto) showed that it may offer clinical benefit and was well tolerated in a small cohort of patients with metastatic castration-resistant prostate cancer (CRPC) who had sustained prostate-specific membrane antigen (PSMA) expression, according to results from a retrospective single-center study shared at the 2025 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.1 Previously, in March 2022, [177Lu]Lu-PSMA-617 was approved for adult...
-
1 week ago | 
cancernetwork.com | Tim Cortese
Adjuvant aspirin did not reduce the rate of recurrence nor improve survival outcomes for patients with colorectal cancer (CRC) liver metastases and cannot be recommended as an adjuvant treatment, according to results from the randomized phase 3 ASAC trial (NCT03326791).1 These findings were shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
1 week ago | 
cancernetwork.com | Tim Cortese
Mezigdomide (Mezi) plus dexamethasone and bortezomib (Velcade; MeziVd) or carfilzomib (Kyprolis; MeziKd) demonstrated promising efficacy and a manageable safety profile across all dose levels in patients with relapsed or refractory multiple myeloma, as shown in the results of the phase 1/2 CC-92480-MM-002 trial (NCT03989414) shared at the European Hematology Association 2025 Congress.
-
1 week ago | 
cancernetwork.com | Tim Cortese
First-line systemic therapy plus radiation therapy for oligoprogressive lesions (m-FLST + RT) may offer clinical benefit without the need for second-line systemic therapy with or without radiation therapy (s-SLST + RT) in the treatment of patients with oligoprogressive hepatocellular carcinoma (HCC), according to results from a study published in the International Journal of Radiation Oncology, Biology, and Physics.
-
1 week ago | 
cancernetwork.com | Tim Cortese
The FDA has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) as a treatment for patients with relapsed or refractory follicular lymphoma, according to a release from the agency.1Supporting results from the double-blind, placebo-controlled phase 3 inMIND trial (NCT04680052) compared the approved combination vs placebo with lenalidomide and rituximab.
-
1 week ago | 
cancernetwork.com | Tim Cortese
LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell product candidate, showed robust clinical responses in the third-line or later treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL) in a multicenter phase 1/2 trial (NCT05826535).
-
1 week ago | 
cancernetwork.com | Tim Cortese
Atebimetinib (IMM-1-104), an oral MEK inhibitor, in combination with modified gemcitabine and nab-paclitaxel (Abraxane) led to positive results, particularly regarding survival, in the frontline treatment of patients with pancreatic cancer in an ongoing phase 2a trial (NCT05585320), according to a press release from the developer, Immuneering Corporation.1 At the data cutoff of May 26, 2025, the overall survival (OS) and progression-free survival (PFS) 6-month rates were 94% (95% CI, 77%-98%)...
-
2 weeks ago | 
onclive.com | Tim Cortese
Findings from a phase 1b trial (NCT05421663) demonstarted that JNJ’4496 (JNJ-90014496) demonstrated antitumor activity and a favorable safety profile at the recommended phase 2 dose of 75 million CAR T cells in patients with relapsed or refractory large B-cell lymphoma (LBCL). The overall response rate (ORR) at the RP2D (n = 22) was 96% (95% CI, 77%-100%), with complete responses (CRs) observed in 77% and partial responses (PRs) in 18%.
-
2 weeks ago | 
cancernetwork.com | Tim Cortese
Primary results from the phase 3 POD1UM-303/InterAACT-2 trial (NCT04472429) showed that retifanlimab-dlwr (Zynyz) added to carboplatin and paclitaxel provided clinical benefit with a manageable safety profile in patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) who have not been treated with systemic chemotherapy, according to a press release from the developer, Incyte.1 Results were shared in The Lancet concurrently with the press...
-
2 weeks ago | 
cancernetwork.com | Tim Cortese
The FDA has granted fast track designation to RAD101, an imaging small molecule that targets fatty acid synthase (FASN), to distinguish between recurrent disease and the treatment effect of brain metastases that originate from different solid tumors including leptomeningeal disease, according to a press release from the developer, Radiopharm Theranostics.1 FASN is a multi-enzyme protein that catalyzes fatty acid synthesis, which is overexpressed in various solid tumors, including cerebral...
